Search Results - nadya+tarasova

6 Results

Sort By:

A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer

This technology includes a new chemical scaffold (with lead compound XL5) against hRpn13 that induces apoptosis, which may have clinical efficacy against cancer. The structure of XL5-conjugated hRpn13 guided the design of XL5-PROTAC degrader compounds that exhibit greater efficacy than previous hRpn13-targeting compounds, as evaluated by selectivity...

Published: 8/12/2024 | Inventor(s): Venkatareddy Sabbasani, Kylie Walters, Xiuxiu Lu, Nadya Tarasova, Rolf Swenson

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Synthetic lipopeptide inhibitors of RAS oncoproteins

Abstract: It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use. Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the...

Published: 6/11/2024 | Inventor(s): Nadya Tarasova, Sergey Tarasov, Vadim Gaponenko, Joseph Kates, Michael Dean, Alla Ivanova

Keywords(s): COLON, LUNG, MULTIPLE MYELOMA, Pancreatic Cancer, RAS, THYROID CANCER

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway

Abstract: Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB...

Published: 4/8/2024 | Inventor(s): Nadya Tarasova, Mercedes Gonzalez-Juarreto

Keywords(s): Anti-infective, IL-10, immunomodulatory, Immunotherapy, INTERLEUKIN, STAT3, TUBERCULOSIS

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents

Abstract: IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases. Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. NCI investigators at the Cancer and Inflammation Program have synthesized short peptides that selectively interfere...

Published: 4/8/2024 | Inventor(s): Nadya Tarasova, Giorgio Trinchieri, Howard Young, C. Andrew Stewart, Marco Cardone, Alan Perantoni

Keywords(s): IFN-gamma, Interferon gamma, INTERLEUKIN, Peptide, Peptidometic, psoriasis, Synthetic Peptide Inhibitors

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Dermatology, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology

Cancer Therapeutic Agents that Bind to STAT Proteins

Abstract: The National Cancer Institute, Cancer and Inflammation Program seeks parties interested in collaborative research to further co-develop inhibitors of STAT proteins for the treatment of cancer. Signal transducer and activator transcription (STAT) proteins, specifically STAT1, 2, 3, 4, 5a, 5b, and 6, are involved in the cellular and biological...

Published: 4/8/2024 | Inventor(s): Nadya Tarasova, Olga Timofeeva, Vadim Gaponenko, Christopher Michejda, Alan Perantoni, Sergey Tarasov

Keywords(s): Autoimmune, N-terminal domain, STAT

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing, Application > Therapeutics

Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs

Abstract: Peptides corresponding to transmembrane domains of a number of integral proteins were discovered to spontaneously self-assemble in aqueous solutions into stable and remarkably uniform nanoparticles. Researchers at the NCI’s Cancer and Inflammation Program have developed fully synthetic, peptide-based, virus-like nanoparticles capable...

Published: 4/8/2024 | Inventor(s): Nadya Tarasova, Sergey Tarasov, Christopher Michejda

Keywords(s): Drug Delivery, GPCR, Hydrophobic Agent, Nanoparticle, Peptide-based Nanoparticle, Synthetic Peptide, Tarasova, VIRUS-LIKE

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology